<DOC>
	<DOCNO>NCT01182376</DOCNO>
	<brief_summary>The primary objective study demonstrate dronedarone ( Multaq® ) may aid slow progression leave atrial ventricular fibrosis patient atrial fibrillation assess late gadolinium enhance magnetic resonance imaging .</brief_summary>
	<brief_title>SOAR : Study Observing Antiarrhythmic Remodelling Using LGE-MRI</brief_title>
	<detailed_description>BACKGROUND AND INTRODUCTION : Atrial fibrillation ( AF ) arise result complex interaction trigger , perpetuators substrate . As early 1995 , Morillo et al demonstrate AF associate ultrastructural change myocytes . In animal model , alteration myocytes sustain AF resemble myocardial hybernation phenotypical adaptation towards fetal stage . Ultimately , structural change would lead Calcium overload metabolic stress , similar change observe human . However , human , atrial dilatation degenerative change observe . Interstitial fibrosis ( cause deposit collagen fibronectin ) prime cause structural remodeling leave atrium ( Boldt et al. , 2004 ) . It well establish fibrosis confound clinical factor cause AF ( Kostin et al. , 2002 ) . But AF promote fibrosis , turn lead increase conduction heterogeneity within atrial substrate result progression AF ( Everett , Olgin , 2007 ) . The recent introduction Late Gadolinium enhancement magnetic resonance imaging ( LGE-MRI ) sequence allow non-invasive assessment location extent arrhythmia relate fibrosis . Contrast enhancement occur result alter washout kinetics gadolinium relative normal surround tissue , may reflect increased fibrosis tissue remodel myocardium . Our group demonstrate feasibility new LGE-MRI acquisition process protocol detect fibrosis LA . To date , control trial evaluate effect antiarrhythmic drug ( AAD ) regression leave atrial fibrosis assess LGE-MRI perform . We propose use LGE-MRI evaluate effect dronedarone vs. placebo atrial ventricular fibrosis . It show success catheter ablation procedure ( show superior term maintain sinus rhythm AF patient compare anti-arrhythmic drug ) dependent upon extent fibrosis ( Akoum et al. , prep ) . In AF patient great 35 % enhancement ( percent leave atrial fibrosis ) , success catheter ablation reduce AF recurrence greatly reduce . Hence patient , drug control progression fibrosis simultaneously provide respite AF recurrence would extremely desirable prescription . Multaq® chosen drug study clinical trial ( Hohnloser et al. , 2009 ) show potential reduce incidence hospitalization due cardiovascular event 25.5 % death AF patient 45 % . We acknowledge information Dronedarone may prone AF recurrence , however , good safety profile regard thyroid neurologic event interfere oral anticoagulant ( Le Heuzey et al. , 2010 ) , make dronedarone preferred antiarrhythmic drug use study . Furthermore , patient take dronedarone post cardioversion procedure revert arrhythmia back normal sinus rhythm ( NSR ) , dronedarone show decrease AF recurrence ( Le Heuzey et al. , 2010 ) . OBJECTIVES : Primary : The primary objective study demonstrate dronedarone may aid regression slow progression leave atrial ventricular fibrosis patient atrial fibrillation assess LGE-MRI , use longitudinal data double-blinded , prospective study patient diagnose atrial fibrillation twelve month follow period . Secondary : - To study effect dronedarone global parameter myocardial remodel right leave atrial volume right leave ventricular volume . - To study correlation AF burden express percentage AF measure 8-day Holter Monitoring three , six twelve month post initiation .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Patients age 18 old Must carry diagnosis Paroxysmal Atrial Fibrillation 1 month longer prior enrol . AAD : Multaq® ( dronedarone ) candidate Patients give informed consent Patients unavailable continue followup University Utah outpatient clinic . Patients weigh &gt; 200 lb ( MR image efficacy decrease due density ) Prior RF Ablation treatment atrial fibrillation Severe renal failure manifest chronic GFR &lt; 30 mL/min , acute renal failure regardless GFR , renal function stabilize . ( Gadolinium contraindication ) Enrollment investigational trial antiarrhythmic therapy Any health relate Gadolinium/MRI contraindication : Pacemaker device , etc . Pregnant woman Individuals cognitive impairment unable give inform consent Multaq® ( dronedarone ) contraindication : NYHA Class IV heart failure NYHA Class II III heart failure recent decompensation require hospitalization referral specialized heart failure clinic Second thirddegree atrioventricular ( AV ) block sick sinus syndrome Bradycardia &lt; 50 bpm Concomitant use strong CYP 3A inhibitor , ketoconazole , itraconazole , voriconazole , cyclosporine , telithromycin , clarithromycin , nefazodone , ritonavir Concomitant use drug herbal product prolong QT interval might increase risk Torsade de Pointes , phenothiazine antipsychotic , tricyclic antidepressant , certain oral macrolide antibiotic , Class I III antiarrhythmic QTc Bazett interval ≥ 500 m PR interval &gt; 280 m Severe hepatic impairment Pregnant woman Nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Multaq</keyword>
	<keyword>dronedarone</keyword>
	<keyword>Atrial Fibrillation</keyword>
</DOC>